Osteoporosis, Periodontitis
Conditions
Keywords
non-surgical periodontal treatment, bisphosphonates, interleukin-1β, interleukin-17, 8-hydroxydeoxyguanosine, alkaline phosphatase
Brief summary
Inflammatory mediators in periodontitis may lead to elevated systemic cytokine levels, resulting in increased bone resorption including the jaws. Osteoporosis may have an influence on the periodontal condition of post-menopausal women and the risk for periodontal disease may increase due to osteoporosis. The hypothesis of the study was that non-surgical periodontal treatment and medical treatment of osteoporosis by bisphosphonates may improve the clinical outcomes and decrease salivary levels of IL-1β, IL-17, ALP and 8-OHdG. Therefore, the aim of this study was to evaluate the mechanism of bi-directional relationship between osteoporosis and periodontal diseases and to investigate the outcomes of non-surgical periodontal treatment with regard to salivary levels of IL-1β, IL-17, 8-OHdG and ALP in patients with periodontitis and osteoporosis.
Interventions
PROCEDUREnon-surgical periodontal treatment
supra- and subgingival scaling, and root planning
Sponsors
Gazi University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
25 patients with periodontitis (P) and osteoporosis (group 1), 25 systemically healthy patients with P (group 2) and 25 systemically and periodontally healthy individuals (group 3) were enrolled in this study. Individuals were periodontally examined at baseline, 1 month and 3 months following the non-surgical periodontal therapy. Participants in group 1 and 2 received non-surgical periodontal therapy including supra- and subgingival scaling, and root planning.Patients were advised and instructed to perform oral care twice a day, use interdental toothbrushes once a day regularly. No scaling and root planning was performed in the group 3.
Eligibility
Sex/Gender
FEMALE
Age
35 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* The participants were postmenopausal patients defined as absence of menstruation for at least 12 months. * Patients with periodontitis; * Patients who had no systemic diseases and were periodontally healthy (no attachment loss), * Patients who were treated with oral bisphosphonate at least one year (70 mg tablet once weekly)
Exclusion criteria
* if they had received any periodontal treatment in the preceding three months, * if they were pregnant or in the period of lactation, * if they had systemic diseases that may interfere with normal healing mechanism, * if they had taken antibiotics, anticonvulsants, immunosuppressants, calcium channel blockers in the preceding six months. * Smokers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| salivary levels of 8-hydroxydeoxyguanosine at 3-month | 3-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of 8-hydroxydeoxyguanosine in g/ml |
| salivary levels of IL-17 at 1-month | 1-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of IL-17 in g/ml |
| salivary levels of IL-17 at 3-month | 3-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of IL-17 in g/ml |
| salivary levels of alkaline phosphatase at baseline | baseline | evaluation of the salivary levels of alkaline phosphatase in g/ml |
| salivary levels of 8-hydroxydeoxyguanosine at baseline | baseline | evaluation of the salivary levels of 8-hydroxydeoxyguanosine in g/ml |
| salivary levels of 8-hydroxydeoxyguanosine at 1-month | 1-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of 8-hydroxydeoxyguanosine in g/ml |
| salivary levels of IL-1β at baseline | baseline | evaluation of the salivary levels of IL-1β in g/ml |
| salivary levels of IL-1β at 1-month | 1-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of IL-1β in g/ml |
| salivary levels of IL-1β at 3-month | 3-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of IL-1β in g/ml |
| salivary levels of IL-17 baseline | baseline | evaluation of the salivary levels of IL-17 in g/ml |
| salivary levels of alkaline phosphatase at 1-month | 1-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of alkaline phosphatase in g/ml |
| salivary levels of alkaline phosphatase at 3-month | 3-month follow-up after non-surgical periodontal therapy | evaluation of the salivary levels of alkaline phosphatase in g/ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| gingival index | baseline, 1- and 3-month follow- up. | gingival index scores assessed at baseline and at 1 month and 3 months after non-surgical periodontal therapy |
| bleeding on probing | baseline, 1- and 3-month follow- up. | bleeding on probing scores assessed at baseline and at 1 month and 3 months after non-surgical periodontal therapy |
| probing depth | baseline, 1- and 3-month follow- up. | probing depth scores assessed at baseline and at 1 month and 3 months after non-surgical periodontal therapy |
| clinical attachment level | baseline, 1- and 3-month follow- up. | clinical attachment level scores assessed at baseline and at 1 month and 3 months after non-surgical periodontal therapy |
| Plaque index | baseline, 1- and 3-month follow- up. | Plaque index scores assessed at baseline and at 1 month and 3 months after non-surgical periodontal therapy |
Countries
Turkey (Türkiye)
Outcome results
None listed